23andMe founder Anne Wojcicki speaks during a House Committee on Oversight and Government Reform hearing in Washington, D.C., on June 10, 2025.
Andrew Harnik | Getty Images
Anne Wojcicki, the co-founder and former CEO of 23andMe, has regained control over the embattled genetic testing company after her latest nonprofit, TTAM Research Institute, outbid Regeneron Pharmaceuticals, the corporate announced Friday.Â
TTAM will acquire substantially all of 23andMe’s assets for $305 million, including its Personal Genome Service and Research Services business lines in addition to telehealth subsidiary Lemonaid Health. It’s an enormous win for Wojcicki, who stepped down from her role as CEO when 23andMe filed for Chapter 11 bankruptcy protection in March.
Last month, Regeneron announced it could purchase most of 23andMe’s assets for $256 million after it got here out on top during a bankruptcy auction. But Wojcicki submitted a separate $305 million bid through TTAM and pushed to reopen the auction. TTAM is an acronym for the primary letters of 23andMe, in keeping with The Wall Street Journal.
“I’m thrilled that TTAM Research Institute will have the opportunity to proceed the mission of 23andMe to assist people access, understand and profit from the human genome,” Wojcicki said in an announcement.
23andMe gained popularity due to its at-home DNA testing kits that gave customers insight into their family histories and genetic profiles. The five-time CNBC Disruptor 50 company went public in 2021 via a merger with a special purpose acquisition company. At its peak, 23andMe was valued at around $6 billion.
The corporate struggled to generate recurring revenue and arise viable research and therapeutics businesses after going public, and it has been tormented by privacy concerns since hackers accessed the data of nearly seven million customers in 2023.
TTAM’s acquisition continues to be subject to approval by the U.S. Bankruptcy Court for the Eastern District of Missouri.
